Walleye Capital
VRDN icon

Walleye Capital’s Viridian Therapeutics VRDN Stock Holding History

Walleye Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$4.32K – 5183
2025
Q3 		$4.32K Buy
+200
New +$3.61K ﹤0.01% 4324
2025
Q2 		– Sell
-8,100
Closed -$109K – 5087
2025
Q1 		$109K Buy
8,100
+600
+8% +$10.2K ﹤0.01% 3583
2024
Q4 		$144K Buy
+7,500
New +$163K ﹤0.01% 3949
2024
Q2 		– Sell
-1,600
Closed -$28K – 6049
2024
Q1 		$28K Sell
1,600
-2,000
-56% -$38.8K ﹤0.01% 4834
2023
Q4 		$78.4K Sell
3,600
-300
-8% -$4.74K ﹤0.01% 4151
2023
Q3 		$59.8K Buy
+3,900
New +$74.4K ﹤0.01% 4140

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Walleye Capital's VRDN Position: Q2 2026 in Review

Walleye Capital sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 54,398 shares — an estimated $1.06M sold.

Walleye Capital first reported a position in VRDN in Q3 2021 and held it in 19 quarters. The position peaked at $12.7M in Q3 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Walleye Capital reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 54,398 Viridian Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Walleye Capital first reported a position in Viridian Therapeutics in Q3 2021 and held it in 19 quarters.
  • Walleye Capital's Viridian Therapeutics position peaked at $12.7M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.